Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Magnetic Resonance Spectroscopy 13pembrolizumab 9Biopsy 9Nivolumab 8Radiotherapy 7Specimen Handling 5Cyclophosphamide 5Temozolomide 4Radiosurgery 4fludarabine 3X-Rays 3Surgical Procedures, Operative 3Rituximab 3Paclitaxel 3Leukapheresis 3Ipilimumab 3Fluorodeoxyglucose F18 3Dexamethasone 3Bevacizumab 3Aspirin 3perflutren 2alovudine 2Vaccines 2Tirzepatide 2Positron-Emission Tomography 2Phantoms, Imaging 2Omeprazole 2Niacinamide 2Neoadjuvant Therapy 2Metastasectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Loratadine × 90 days × Clear all
NCT04211259 2026-05-29

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡